Cite
HARVARD Citation
Agulnik, M. et al. (2021). An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. European journal of cancer. pp. 201-208. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Agulnik, M. et al. (2021). An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. European journal of cancer. pp. 201-208. [Online].